ライフサイエンスコーパス: microangiopathy

1 with either C3 glomerulopathy or thrombotic microangiopathy).

2 MTS13 deficiency does not lead to continuous microangiopathy.

3 estive of hypertensive or arteriolosclerotic microangiopathy.

4 c anemia, and AKI with glomerular thrombotic microangiopathy.

5 ch may contribute to formation of thrombotic microangiopathy.

6 CoV-2, severe pneumonia and life-threatening microangiopathy.

7 c syndrome (DHUS), a severe renal thrombotic microangiopathy.

8 nical endothelial dysfunction precedes overt microangiopathy.

9 y of life, and increased risk for thrombotic microangiopathy.

10 herapy; and they had a greater prevalence of microangiopathy.

11 e of a membranoproliferative-like glomerular microangiopathy.

12 ic disease of complement-mediated thrombotic microangiopathy.

13 hese changes vary according to the degree of microangiopathy.

14 ies, dependent on the presence or absence of microangiopathy.

15 purpura (TTP), a life-threatening thrombotic microangiopathy.

16 perglycemia and the appearance of structural microangiopathy.

17 in the development of glomerular thrombotic microangiopathy.

18 thereby interconnecting macroangiopathy and microangiopathy.

19 OF syndrome can have VWF-mediated thrombotic microangiopathy.

20 enal tissues, two target tissues of diabetic microangiopathy.

21 iagnosed with posttransplantation thrombotic microangiopathy.

22 inantly from the development of a thrombotic microangiopathy.

23 peripheral arterial disease, as well as with microangiopathy.

24 rated interest as a marker of bleeding-prone microangiopathy.

25 ckening, a histological hallmark of diabetic microangiopathy.

26 There were no episodes of thrombotic microangiopathy.

27 breakdown of homeostatic balance in diabetic microangiopathy.

28 ink in the pathogenesis of POAG and diabetic microangiopathy.

29 ost other manifestations of diabetic retinal microangiopathy.

30 tients with transplant-associated thrombotic microangiopathy.

31 enia, hemolytic anemia, and renal thrombotic microangiopathy.

32 ith 9 +/- 5 years of diabetes and documented microangiopathy.

33 , but there was no evidence of haemolysis or microangiopathy.

34 othelins to vascular dysfunction in diabetic microangiopathy.

35 lved in the pathogenesis of diabetic retinal microangiopathy.

36 olytic uremic syndrome, a form of thrombotic microangiopathy.

37 uremic syndrome (aHUS) is a rare thrombotic microangiopathy.

38 ted in transplantation-associated thrombotic microangiopathy.

39 osits, which are classic signs of thrombotic microangiopathy.

40 h Covid-19 showed widespread thrombosis with microangiopathy.

41 diagnostic challenge presented by thrombotic microangiopathy.

42 lement, endothelial barrier dysfunction, and microangiopathy.

43 , proteinuria, renal failure, and thrombotic microangiopathy.

44 at plasminogen activation takes place during microangiopathy.

45 is and treatment of TTP and other thrombotic microangiopathies.

46 cifications or all the diabetic-like retinal microangiopathies.

47 ring pathogenesis of Stx-mediated thrombotic microangiopathies.

48 considered within the group of thrombocytic microangiopathies.

49 erstitial hemorrhages (31.6%), or thrombotic microangiopathy (15.8%).

50 t in pregnancy or postpartum as a thrombotic microangiopathy, a life-threatening condition that may i

51 C score-to stratify patients with thrombotic microangiopathy according to their risk of having severe

52 ggest that mechanisms other than generalized microangiopathy account for the altered CMRglu observed

53 sponse to endotoxin < 200 pg/mL), thrombotic microangiopathy (ADAMTS13 activity <57%), and EBV seropo

54 ated tau; and cerebral amyloid angiopathy, a microangiopathy affecting both cerebral cortical capilla

55 2 (n = 10), grafts also developed thrombotic microangiopathy affecting mainly the glomeruli by day 30

56 Dermatomyositis is a microangiopathy affecting skin and muscle; activation an

57 Thrombotic microangiopathy after allogeneic HSCT shares similaritie

58 als developed severe C5-dependent thrombotic microangiopathy after induction of complement activation

59 ead to insulin resistance, hypertension, and microangiopathy, all of which are associated with type 2

60 Age-related microangiopathy, also known as small vessel disease (SVD

61 Diabetes mellitus accelerates cardiovascular microangiopathies and atherosclerosis, which are a conse

62 y have therapeutic value in the treatment of microangiopathies and may be useful to bypass inhibitory

63 Renal microangiopathies and membranoproliferative GN (MPGN) ca

64 ars of diabetes and histological evidence of microangiopathy and 18 age-matched nondiabetic donors we

65 centres in Boston, MA, USA, with thrombotic microangiopathy and a possible diagnosis of thrombotic t

66 otected homozygous C3KI mice from thrombotic microangiopathy and aHUS.

67 major risk factor for glomerular or retinal microangiopathy and cardiovascular complications of type

68 3 mg/d; P < 0.01); and abrogated thrombotic microangiopathy and decreased plasma aldosterone (<16 ve

69 attenuated histone-induced renal thrombotic microangiopathy and glomerular necrosis in mice.

70 t required for the development of thrombotic microangiopathy and HUS induced by EHEC Shiga toxins in

71 njury, cortical volume loss, mineralization, microangiopathy and neurocognitive impairment in survivo

72 Acute arteriolar thrombotic microangiopathy and onion skinning were associated with

73 , proteinuria (17 +/- 9 mg/d) and thrombotic microangiopathy and plasma aldosterone (18 +/- 18 pg/ml)

74 ity between the diabetic macroangiopathy and microangiopathy and suggests a molecular explanation beh

75 Microangiopathy and vascular disease also contribute to

76 erized by vascular lesions (e.g., thrombotic microangiopathy and vasculitis) is a hallmark of type 1

77 mab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time

78 ociated antigens was an early feature of the microangiopathy and was associated with thickening of th

79 ema, red cell extravasation, rare thrombotic microangiopathy, and complement deposition.

80 st disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment correlated wit

81 inflammation, endothelial damage, thrombotic microangiopathy, and end-organ damage.

82 lantation/chemotherapy-associated thrombotic microangiopathy, and in the hemolytic-uremic syndrome, i

83 tubular swelling, vacuolization, thrombotic microangiopathy, and increased expression of TGF-beta, c

84 eased in adults with VWF-mediated thrombotic microangiopathy, and intensive plasma exchange (PEx) bot

85 matrix and platelet aggregation, thrombotic microangiopathy, and neutrophilic infiltration.Sublytic

86 Creatinine, acute arteriolar thrombotic microangiopathy, and onion skinning in small arteries we

87 pillary hypercellularity, 1 focal glomerular microangiopathy, and the others no significant glomerula

88 manifested with acute and chronic thrombotic microangiopathy; and (c) EC proinflammatory changes: inc

89 P syndrome, transplant-associated thrombotic microangiopathy, antiphospholipid antibody syndrome, mya

90 like, classically associated with thrombotic microangiopathy are the hemolytic-uremic syndrome (HUS)

91 to establish posttransplantation thrombotic microangiopathy as a discrete clinical or pathologic ent

92 e dropout may avoid or attenuate the retinal microangiopathy associated with diabetes.

93 might be effective in repairing the coronary microangiopathy associated with hypertension-induced LVH

94 - and endotheliumum-based selectin-dependent microangiopathy associated with mucin-producing carcinom

95 requently called upon to diagnose thrombotic microangiopathy, be aware of its association with ticlop

96 ical hemolytic uremic syndrome as thrombotic microangiopathy), biopsy appearance (dense deposit disea

97 nly identify a genetic cause of a glomerular microangiopathy but also suggest that the phosphatidylin

98 ll cells are potential informers of diabetic microangiopathy but may be preempted from carrying out r

99 1%), associated mainly with late thrombotic microangiopathy (C: 78%; C3: 11% of cases).

100 Thrombotic microangiopathies can be associated with defective regul

101 c syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogenic variants

102 lytic uremic syndrome (aHUS) is a thrombotic microangiopathy caused by uncontrolled activation of the

103 syndrome is a complement-mediated thrombotic microangiopathy caused by uncontrolled activation of the

104 olytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis

105 P) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemoly

106 family with patients affected by thrombotic microangiopathy characterized by significant serum compl

107 remic syndrome (aHUS) is a severe thrombotic microangiopathy characterized by uncontrolled complement

108 Complement-mediated thrombotic microangiopathy (CM-TMA) or hemolytic uremic syndrome, p

109 4 women with aHUS from the Vienna Thrombotic Microangiopathy Cohort.

110 c syndrome (aHUS) is a rare renal thrombotic microangiopathy commonly associated with rare genetic va

111 owed no significant improvements in diabetic microangiopathy, confirming the unique role of the pancr

112 sults indirectly support the hypothesis that microangiopathy contributes to structural nerve damage i

113 rpura, in which life-threatening episodes of microangiopathy damage kidneys, heart, and brain.

114 f these cells in the pathogenesis of retinal microangiopathy deserves to be investigated.

115 months, the patient had relapsing thrombotic microangiopathy despite plasma exchange; splenectomy; an

116 toantibodies is associated with a thrombotic microangiopathy disease, atypical hemolytic uremic syndr

117 d diabetic subjects with very early diabetic microangiopathy (DMA+) (n = 16).

118 also more consistently diagnosed thrombotic microangiopathy due to severe ADAMTS13 deficiency than d

119 However, the distinction among thrombotic microangiopathy etiologies in pregnancy is important bec

120 e platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the pl

121 trial 2, 80% of the patients had thrombotic microangiopathy event-free status.

122 emolytic-uremic syndrome (HUS), a thrombotic microangiopathy, following infections by Shiga toxin-pro

123 ng pregnancy, and implications of thrombotic microangiopathies for subsequent pregnancies are evolvin

124 r frequency is six-fold higher in thrombotic microangiopathy forms associated with bone marrow transp

125 f the French Reference Center for Thrombotic Microangiopathies from 2000-2010 to identify all women w

126 e different datasets containing MR images of microangiopathy, glioblastoma, and multiple sclerosis.

127 pathway that are associated with thrombotic microangiopathies, glomerulonephritides, and chronic con

128 th bone marrow transplant-related thrombotic microangiopathy had anti-factor H IgM autoantibodies ver

129 in diabetic patients with absent or minimal microangiopathy have pointed to possible dysfunction of

130 In a mouse model of thrombotic microangiopathy, HDL also largely prevented the thromboc

131 lication, including preeclampsia, thrombotic microangiopathy, heart failure, sepsis, or postpartum he

132 e inability to reproduce HUS with thrombotic microangiopathy, hemolytic anemia, and acute kidney inju

133 olytic uremic syndrome, including thrombotic microangiopathy, hemolytic anemia, thrombocytopenia, and

134 newly established mouse model of thrombotic microangiopathy highly predictive for investigating the

135 , untreated transplant-associated thrombotic microangiopathy (hrTMA) has dismal outcomes due to multi

136 In diabetic microangiopathy, hyperglycemia induces biochemical and m

137 ase series of posttransplantation thrombotic microangiopathy illustrates uncertainties regarding inci

138 R was associated with subclinical thrombotic microangiopathy in 2 patients.

139 lls (HUVECs), and Stx2B can cause thrombotic microangiopathy in Adamts13(-/-) mice.

140 he isolated Stx2B subunits induce thrombotic microangiopathy in Adamts13(-/-) mice.

141 more sensitive than FA in detecting macular microangiopathy in asymptomatic patients.

142 triggers may be required to cause thrombotic microangiopathy in many patients.

143 ignant nephrosclerotic lesions of thrombotic microangiopathy in salt-loaded, stroke-prone, spontaneou

144 noninvasively and objectively study diabetic microangiopathy in the conjunctival microcirculation of

145 prominent, such as development of thrombotic microangiopathy in the graft or systemic consumptive coa

146 omplicated by a potentially fatal thrombotic microangiopathy in the recipient baboons.

147 arked interstitial hemorrhage and thrombotic microangiopathy in the renal vasculature.

148 ibility to glomerular endothelial injury and microangiopathy in two genetic murine models that includ

149 ctive values for both cardiac and peripheral microangiopathy in type 2 diabetes (T2D).

150 mplement-induced blood clotting and systemic microangiopathy - in disease exacerbation.

151 een demonstrated to predispose to thrombotic microangiopathies including atypical hemolytic uremic sy

152 ly stages, the pathology is characterized by microangiopathies, including microaneurysms, microhemorr

153 re examined by light microscopy for possible microangiopathy, including changes in endothelial cell-t

154 aldosterone in the development of thrombotic microangiopathy, independent of hypertension.

155 hese data are consistent with a mechanism of microangiopathy involving endothelial cell injury (assoc

156 The hallmark of all thrombotic microangiopathies is vascular endothelial cell injury of

157 Thrombotic microangiopathy is a significant complication of HIV inf

158 Thrombotic microangiopathy is a significant complication with this

159 Diabetic retinal microangiopathy is characterized by increased permeabili

160 Thrombotic microangiopathy is characterized by microvascular thromb

161 such pregnancies for episodes of thrombotic microangiopathy is essential but, the best strategy to p

162 A complement-induced microangiopathy is important in dermatomyositis and in t

163 trum of complement-mediated renal thrombotic microangiopathy is still a matter of debate.

164 uremic syndrome (aHUS), a severe thrombotic microangiopathy, is often related to complement dysregul

165 ment of T3SS-dependent intestinal thrombotic microangiopathy (iTMA) and ischemic enteritis in approxi

166 , as are present in patients with thrombotic microangiopathy, lack an inhibitory effect on complement

167 cular integrity in the degenerative cerebral microangiopathies leading to stroke and dementias.

168 eatening disease characterized by thrombotic microangiopathy leading to end-organ damage.

169 (78 +/- 7 mg/d) were greater and thrombotic microangiopathy lesions were comparable to SHAM.

170 ng the box C/D snoRNA U8, cause the cerebral microangiopathy leukoencephalopathy with calcifications

171 ic purpura (cTTP) is an ultrarare thrombotic microangiopathy mediated through inherited deficiency in

172 nephritis (n = 3), HIV-associated thrombotic microangiopathy (n = 1), and HIV-negative patients with

173 flammation to AKI is discussed in thrombotic microangiopathies, necrotizing and crescentic GN, acute

174 process likely contributes to the thrombotic microangiopathy observed after PBPC transplantation in t

175 TGF-beta as an important contributor to the microangiopathy of diabetic retinopathy and nephropathy.

176 rombocytopenic purpura (TTP) is a thrombotic microangiopathy of obscure etiology.

177 phalopathy syndrome (PRES) is a small vessel microangiopathy of the cerebral vasculature that occurs

178 Microangiopathy of the pre-diabetic and diabetic type ch

179 ion, two patients had findings of thrombotic microangiopathy, one had pauci-immune crescentic GN, and

180 BMBs might only be a biomarker for microangiopathy, or alternatively BMBs might provide use

181 WF in SCD pathology and connect SCD to other microangiopathies, particularly thrombotic thrombocytope

182 rove useful in the future care of thrombotic microangiopathy patients and might be a rational basis f

183 lates with clinical parameters in thrombotic microangiopathy patients.

184 this was later correlated with disseminated microangiopathy (platelet-rich clots in small blood vess

185 tanding the pathogenesis of other thrombotic microangiopathies, post-HSCT TMA remains poorly understo

186 or reactivity, which might indicate cerebral microangiopathy, predicted depressive disorders only, in

187 Posttransplantation thrombotic microangiopathy (PTMA) is a complication of allogeneic h

188 o be an important risk factor for thrombotic microangiopathy rather than a specific diagnostic marker

189 n the French Reference Center for Thrombotic Microangiopathies registry between 2000 and 2016 were de

190 Posttransplantation thrombotic microangiopathy remains a diagnostic and therapeutic cha

191 Thrombotic microangiopathy resolved with discontinuation of the dru

192 patients had achieved a complete thrombotic microangiopathy response.

193 % of patients achieved a complete thrombotic microangiopathy response; 94.4%, 88.9% and 83.3% of pati

194 We hypothesized that microangiopathy, resulting from long-standing systemic h

195 in DGKE-associated aHUS patients, thrombotic microangiopathy results from impaired EC proliferation a

196 with biopsy-proven de novo renal thrombotic microangiopathy (RTMA), occurring 5 to 120 d (median, 14

197 reduced (>20%) in other forms of thrombotic microangiopathy secondary to hematopoietic progenitor ce

198 tients with transplant-associated thrombotic microangiopathy should be screened for the causes of CD.

199 tive roles in the pathogenesis of thrombotic microangiopathy, SHRSP were adrenalectomized and infused

200 y of the changes described relate to retinal microangiopathy, since ultrastructural, structural, and

201 Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenging diagnosis afte

202 Transplant-associated thrombotic microangiopathy (TA-TMA) is a common and poorly recogniz

203 transplantation (HSCT)-associated thrombotic microangiopathy (TA-TMA) is not completely understood.

204 Transplant-associated thrombotic microangiopathy (TA-TMA) occurs frequently after hematop

205 pients with transplant-associated thrombotic microangiopathy (TA-TMA), and untreated patients have di

206 molytic-uremic syndrome (HUS) are thrombotic microangiopathies that occur in the absence of an inflam

207 reating the hyperinflammation and thrombotic microangiopathy that appear to contribute to the severit

208 o a hyper-inflammatory status and thrombotic microangiopathy that are observed in severe COVID-19 dis

209 rome (aHUS) is a life-threatening thrombotic microangiopathy that can progress, when untreated, to en

210 represents a specific variant of thrombotic microangiopathy that is characterized by glomerular endo

211 olytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is characterized by microangiopathi

212 the evaluation and management of thrombotic microangiopathy that occurs following allogeneic hematop

213 pura (iTTP) is a life-threatening thrombotic microangiopathy that presents with microangiopathic hemo

214 re was no evidence of spontaneous thrombotic microangiopathy, the hepatocyte-specific FH-deficient an

215 that fuels hyperinflammation and thrombotic microangiopathy, thereby increasing coronavirus 2019 (CO

216 patients with posttransplantation thrombotic microangiopathy; these criteria may result in a clearer

217 explain many of the clinical manifestations (microangiopathy, thrombocytopenia, renal injury, and thr

218 ng the syndromes characterised by thrombotic microangiopathy, thrombotic thrombocytopenic purpura is

219 We show that cerebral microangiopathy thus partly explains stroke severity in

220 mune system in the development of thrombotic microangiopathy (TM) after alpha1,3-galactosyltransferas

221 transplantation (BMT)-associated thrombotic microangiopathy (TM) contributes to transplant-related m

222 Thrombotic microangiopathy (TM) is associated with abnormalities of

223 ism, however, results in a severe thrombotic microangiopathy (TM) that includes pronounced thrombocyt

224 ism, however, results in a severe thrombotic microangiopathy (TM) that includes pronounced thrombocyt

225 ism, however, results in a severe thrombotic microangiopathy (TM) that includes vascular injury, micr

226 All failing grafts exhibited thrombotic microangiopathy (TM) with platelet-rich fibrin thrombi i

227 All grafts developed thrombotic microangiopathy (TM).

228 contributes to the development of thrombotic microangiopathy (TMA) after hematopoietic stem cell tran

229 n of impaired C regulation in the thrombotic microangiopathy (TMA) atypical hemolytic uremic syndrome

230 TP) is an acute, life-threatening thrombotic microangiopathy (TMA) caused by acquired or congenital s

231 lytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by excessive activat

232 Thrombotic microangiopathy (TMA) commonly involves injury of kidney

233 have described the occurrence of thrombotic microangiopathy (TMA) following IV abuse of extended-rel

234 Calcineurin inhibitor-induced thrombotic microangiopathy (TMA) has been described in up to 14% of

235 Thrombotic microangiopathy (TMA) has been increasingly reported in

236 Thrombotic microangiopathy (TMA) in renal transplants (rTx-TMA) is

237 cell transplant (HSCT)-associated thrombotic microangiopathy (TMA) is a complication that occurs in 2

238 Thrombotic microangiopathy (TMA) is a life-threatening condition th

239 Thrombotic microangiopathy (TMA) is a well-known complication after

240 Thrombotic microangiopathy (TMA) is a well-recognized complication

241 Transplant-associated thrombotic microangiopathy (TMA) leads to generalized endothelial d

242 Thrombotic microangiopathy (TMA) occurring after allogeneic hematop

243 Thrombotic microangiopathy (TMA) occurs in IgA nephropathy, but its

244 Thrombotic microangiopathy (TMA) significantly predicted graft fail

245 us adverse side effects of FK506, thrombotic microangiopathy (TMA) stands out as an infrequent but se

246 olytic uremic syndrome, a type of thrombotic microangiopathy (TMA) that causes renal failure.

247 uremic syndrome (aHUS) develop a thrombotic microangiopathy (TMA) that in most cases is attributable

248 proliferative lesions, glomerular thrombotic microangiopathy (TMA) was found as a common genetic back

249 veno-occlusive disease (VOD) and thrombotic microangiopathy (TMA) were lower in the nonsirolimus arm

250 nt activation has a major role in thrombotic microangiopathy (TMA), a disorder that can occur in a va

251 inflammatory responses, including thrombotic microangiopathy (TMA), acute kidney injury due to atypic

252 d complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage.

253 nt activity, the development of a thrombotic microangiopathy (TMA), and widespread end organ injury.

254 Many patients with syndromes of thrombotic microangiopathy (TMA), including thrombotic thrombocytop

255 re associated with a rare form of thrombotic microangiopathy (TMA), known as atypical hemolytic uremi

256 hemolytic uremic syndrome (HUS), thrombotic microangiopathy (TMA), or HUS-like events, exceeding the

257 us-2 (HIV-2) strain develop renal thrombotic microangiopathy (TMA), which morphologically resembles a

258 drugs have been reported to cause thrombotic microangiopathy (TMA), yet evidence supporting a direct

259 mplement components in regions of thrombotic microangiopathy (TMA).

260 ry that shares many features with thrombotic microangiopathy (TMA).

261 yndrome (aHUS), the prototypes of thrombotic microangiopathy (TMA).

262 sk periods for different forms of thrombotic microangiopathy (TMA).

263 considered to be caused by severe thrombotic microangiopathy (TMA).

264 is associated with renal-specific thrombotic microangiopathy (TMA).

265 aris degeneration, and glomerular thrombotic microangiopathy (TMA).

266 ate immunity, as characterized by thrombotic microangiopathy (TMA).

267 picture consistent with an acute thrombotic microangiopathy (TMA).

268 transplant, along with widespread thrombotic microangiopathy (TMA).

269 s TTP from HUS and other types of thrombotic microangiopathy (TMA); therefore, the term TTP/HUS shoul

270 The thrombotic microangiopathies (TMAs) and C3 glomerulopathies (C3Gs)

271 Thrombotic microangiopathies (TMAs) are a group of life-threatening

272 the second hit for development of thrombotic microangiopathies (TMAs), a group of life-threatening di

273 explore the relationships of early diabetic microangiopathy to alterations of cardiac sympathetic to

274 Endothelial dysfunction links thrombotic microangiopathy to steroid-refractory graft-versus-host

275 ice developed spontaneous chronic thrombotic microangiopathy together with hematuria, thrombocytopeni

276 Identifying the underlying thrombotic microangiopathy trigger can be challenging but is impera

277 nstrated biological recurrence of thrombotic microangiopathy under treatment.

278 d intravascular coagulopathy associated with microangiopathy, verrucous endocarditis, and arterial em

279 specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of

280 The overall incidence of thrombotic microangiopathy was 19%, and it was significantly higher

281 Thrombotic microangiopathy was an adverse event unique to the TBI a

282 Significant improvement in microangiopathy was observed in all post-SPK diabetics (

283 l growth factor (VEGF) results in thrombotic microangiopathy, we addressed the possibility that Gsalp

284 Although the microangiopathies were ameliorated by AL-3152 treatment

285 (MA(+): n = 49) and without (MA(-): n = 52) microangiopathy were compared with 48 healthy control su

286 214 patients with thrombotic microangiopathy were included in the derivation cohort.

287 ignificant improvements (P<0.05) in diabetic microangiopathy were observed in all 12 diabetics 18 mon

288 a group of conditions termed the thrombotic microangiopathies, which are characterized by prominent

289 hic hemolytic anemia characterize thrombotic microangiopathy, which includes two major disorders: thr

290 hat result in a common pathology, thrombotic microangiopathy, which is classically characterised by t

291 ng data on the risk of developing thrombotic microangiopathy while on Ticlopidine and the possible me

292 A patient who developed thrombotic microangiopathy while on ticlopidine therapy is reported

293 cts of the pathophysiology of the thrombotic microangiopathies will be discussed.

294 Amelioration of galactose-induced retinal microangiopathies with AL-3152 in the prevention group s

295 DM is an undeniably a complement-mediated microangiopathy with destruction of capillaries, hypoper

296 Systemic sclerosis (SSc) is characterized by microangiopathy with impaired reparative angiogenesis an

297 he first reported pontine autosomal dominant microangiopathy with leukoencephalopathy (PADMAL) family

298 lytic uremic syndrome (aHUS) is a thrombotic microangiopathy with severe renal injury secondary to an

299 ury and in particular developed a thrombotic microangiopathy, with mesangiolysis, endothelial swellin

300 sociated with graft failure was a thrombotic microangiopathy, with resulting ischemic injury.